HIV Surveillance in a Large, Community-Based Study: Results from the Pilot Study of Project Accept (HIV Prevention Trials Network 043)

Table 1 HIV rapid tests and chemiluminescent immunoassays used at study sites*

	Thailand	Tanzania	Zimbabwe	South Africa Vulindlela	South Africa Soweto
Assay #1	Determine HIV 1/2^a	Determine HIV 1/2^a	Determine HIV 1/2^a	Determine HIV 1/2^a	Determine HIV 1/2^a
Assay #2	Bioline HIV1/2^a,b	SD Bioline HIV 1/2 v3^a	Uni-Gold HIV^a	SD Bioline HIV 1/2 v3^a	SD Bioline HIV 1/2 v3^a or Uni-Gold HIV^a
Assay #3 (tie-breaker)	Clearview* HIV 1/2 STAT-PAK^c	Uni-Gold HIV^a	OraQuick HIV-1/2 Rapid Antibody Test^c	ARCHITECT HIV Ag/Ab Combo CMIA^c	ARCHITECT HIV Ag/Ab Combo CMIA^c

* The following assays were used in the study: Determine HIV 1/2 (Inverness Medical Innovations, Petchabun, Japan), SD Bioline HIV 1/2 version 3 (Youngin-Si, South Korea), Bioline HIV 1/2 (Petchaboon, Thailand), Uni-Gold HIV (Trinity Biotech plc, Bray, Ireland), Clearview HIV 1/2 STAT-PAK (Inverness Medical Innovations, Waltham, MA), OraQuick HIV 1/2 Rapid Antibody Test (OraSure Technologies, Inc., Bethlehem, PA), ARCHITECT HIV Ag/Ab Combo (Abbott Diagnostics, Wiesbaden, Germany). CMIA: chemiluminescent microparticle immunoassay.
^a Recommended by the USAID [pdf.usaid.gov/pdf_docs/PNADO095.pdf] accessed 11/23/10 - HIV Test Kits Listed in the USAID Source and Origin Waiver: Procurement Information Document, Fifth Edition, Edited by Abiola Johnson, January 2009].
^b Cleared by the Thailand Food and Drug Administration.
^c Cleared by the United States Food and Drug Administration.

ISSN: 1471-2334